YOLFTbeta
Spyre Therapeutics Inc.

Spyre Therapeutics Inc.

SYRE · NASDAQ · Healthcare / Biotechnology

104.00USD+1.09 (+1.06%)

Price History

Full chart

Market Stats

Previous Close102.91
Open102.33
Day Range100.49 – 104.50
52-Week Range15.86 – 110.18
Volume743.88K
Market Cap7.45B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.92
Dividend Yield0.00%
Beta3.00
50-Day Avg96.82
200-Day Avg66.52

About

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Cameron Turtle DPHIL, Ph.D.
  • Employees125
  • HeadquartersBuilding 23, Waltham, MA, United States, 02453, USA
  • Websitehttps://www.spyre.com

Leadership

  • Dr. Cameron Turtle DPHIL, Ph.D.CEO & Director · b. 1990
  • Mr. Scott L. BurrowsChief Financial Officer · b. 1977
  • Ms. Heidy Abreu King-Jones J.D., L.L.M.Chief Legal Officer & Corporate Secretary · b. 1983
  • Dr. Sheldon Sloan M.B.E., M.D.Chief Medical Officer · b. 1959
  • Dr. Janet Gunzner-Toste M.B.A., Ph.D.Senior Vice President of Operations
  • Mr. Brian ConnollyChief Technical Officer
  • Mr. Eric McIntyreSenior Vice President of Finance & Investor Relations
  • Mr. James MyersSenior Vice President of Quality & Compliance
  • Dr. Justin LaFountaine Ph.D.Senior Vice President of Corporate Development
  • Ms. Melissa CooperSenior Vice President of People

Financials

Income Statement

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-6.08M4.63M5.21M3.89M0018.74M2.33M886.00K886.00K0
Growth (%)---23.94%+12.47%-25.30%-100.00%---87.57%-61.96%0.00%-100.00%
Cost of Revenue19.00K89.00K---901.00K1.62M2.00M1.96M964.00K964.00K171.65M
Gross Profit-19.00K6.00M4.63M5.21M3.89M-901.00K-1.62M18.74M2.33M-78.00K886.00K-171.65M
Gross Margin-98.54%100.00%100.00%100.00%--100.00%100.00%-8.80%100.00%-
Operating Expense8.88M17.31M26.53M32.88M49.35M79.43M79.86M84.39M87.11M242.22M209.45M37.91M
Operating Income-8.90M-11.31M-21.91M-27.68M-45.46M-80.33M-81.48M-65.65M-84.78M-242.30M-208.57M-209.56M
Operating Margin--185.95%-473.34%-531.72%-1169.32%---350.33%-3640.23%-27347.97%-23540.18%-
EBITDA-10.33M-11.23M-21.77M-27.43M-45.17M-77.35M-79.27M-64.08M-81.99M-242.30M-207.97M-209.56M
EBITDA Margin--184.49%-470.48%-526.94%-1161.78%---341.98%-3520.27%-27347.97%-23472.57%-
Net Income-10.35M-11.29M-21.70M-27.24M-44.35M-78.25M-80.89M-65.80M-83.81M-338.79M-208.02M-155.20M
Net Income Margin--185.62%-468.84%-523.27%-1140.64%---351.14%-3598.75%-38238.15%-23478.33%-
R&D6.83M11.45M18.14M22.82M36.72M64.60M59.64M57.07M58.58M89.50M162.79M171.65M
R&D as % of Total Revenue-188.22%392.03%438.33%944.42%--304.55%2515.20%10102.03%18373.59%-

Balance Sheet

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.60M2.93M38.65M67.06M56.08M77.74M83.18M161.62M109.93M71.14M341.86M608.48M777.78M
Total Liabilities1.41M1.06M2.55M4.10M5.74M10.31M23.10M21.79M25.98M20.84M157.84M90.68M62.55M
Total Equity3.19M1.87M36.10M62.97M50.34M67.43M60.08M139.83M83.94M50.30M184.02M517.80M715.24M
Cash4.60M2.62M29.29M47.75M12.82M22.46M19.25M90.09M15.14M34.86M188.89M89.42M85.72M
Total Debt------5.12M5.45M5.06M4.63M84.56M84.56M-
Net Debt-4.60M-2.62M-29.29M-47.75M-12.82M-22.46M-14.13M-84.65M-10.08M-30.23M-104.34M-89.42M-85.72M

Cash Flow

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.33M-10.98M-18.84M-24.61M-32.19M-65.69M-75.78M-53.72M-80.14M-99.91M-157.41M-169.25M
Investing Cash Flow-221.00K-4.01M-12.16M-22.53M-15.23M-1.74M-7.60M-22.62M57.01M--353.29M-143.47M
Financing Cash Flow5.58M41.67M49.37M12.21M57.07M65.72M154.51M1.39M42.68M361.08M410.91M309.02M
Capital Expenditure181.00K208.00K212.00K619.00K422.00K1.49M4.28M573.00K38.00K000
Free Cash Flow-7.52M-11.19M-19.05M-25.23M-32.62M-67.18M-80.06M-54.29M-80.18M-99.91M-157.41M-169.25M
FCF to OCF102.47%101.89%101.13%102.51%101.31%102.27%105.65%101.07%100.05%100.00%100.00%100.00%

Earnings

Report DateMay 19, 2016Aug 9, 2016Nov 9, 2016Mar 8, 2017May 9, 2017Aug 9, 2017Nov 7, 2017Mar 13, 2018May 8, 2018Aug 9, 2018Nov 8, 2018Mar 7, 2019May 7, 2019Aug 6, 2019Nov 6, 2019Feb 24, 2020May 7, 2020Aug 10, 2020Nov 5, 2020Mar 18, 2021May 10, 2021Aug 5, 2021Nov 4, 2021Mar 8, 2022May 5, 2022Aug 4, 2022Nov 3, 2022Mar 2, 2023May 11, 2023Aug 11, 2023Nov 9, 2023Feb 29, 2024May 9, 2024Aug 7, 2024Nov 7, 2024Feb 26, 2025May 8, 2025Aug 5, 2025Nov 4, 2025Feb 19, 2026May 7, 2026Aug 4, 2026Nov 3, 2026
EPS Estimate-12.16-10.50-13.59-0.46-11.70-12.00-13.77-0.53-11.51-8.62-10.80-0.37-13.80-12.08-13.31-0.67-16.41-10.76-9.97-0.34-3.49-4.30-7.34-7.63-0.34-7.75-5.87-0.23-4.37-3.50-0.84-0.78-1.08-0.91-0.86-0.94-0.84-0.71-0.74-0.80-0.64-0.71-0.80
EPS Actual-8.80-11.50-11.75-0.56-11.75-11.75-12.00-9.75-12.25-11.50-13.50-15.50-14.75-13.75-16.50-16.25-14.25-10.00-7.25-8.75-7.00-2.50-7.75-7.75-9.25-6.75-4.75-5.00-5.00-56.75-9.34-4.05-1.20-0.86-1.36-0.81-0.60-0.49-0.15-0.74-0.74-0.36-
Surprise27.63%-9.52%13.54%-21.74%-0.43%2.08%12.85%-1739.62%-6.43%-33.41%-25.00%-4089.19%-6.88%-13.82%-23.97%-2325.37%13.16%7.06%27.28%-2451.76%-100.57%41.86%-5.59%-1.57%-2609.43%12.90%19.08%-2090.10%-14.42%-1521.43%-1011.90%-419.23%-11.11%5.49%-58.14%14.22%28.57%30.99%79.73%7.50%-14.84%49.30%-
TimingPre-marketPre-marketPre-market-Pre-marketAfter-hoursAfter-hours-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-Pre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap7.45B
Enterprise Value6.78B
Trailing P/E0.00
Forward P/E0.00
Price / Sales650.22
Price / Book8.14
EPS-1.92
Book Value10.84
Revenue (TTM)0
Gross Profit (TTM)-215.80M
EBITDA-207.82M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-22.98%
Return on Assets-19.81%
Shares Outstanding86.84M
Shares Float82.14M
Beta3.00
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 11 analystsTarget 120.08
  • Strong Buy
    10
  • Hold
    1

Ownership Breakdown

Institutions
110.73%
Insiders
5.70%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    11.78M13.36%
  • BlackRock Inc
    5.52M6.26%
  • Perceptive Advisors LLC
    4.32M4.90%
  • RTW INVESTMENTS, LLC
    4.17M4.73%
  • Fairmount Funds Management LLC
    4.02M4.56%
  • Paradigm Biocapital Advisors LP
    3.84M4.36%
  • VR Adviser, LLC
    3.69M4.18%
  • Vanguard Capital Management, LLC
    3.06M3.47%
  • Driehaus Capital Management LLC
    2.79M3.17%
  • State Street Corp
    2.61M2.96%
  • Capital World Investors
    2.32M2.63%
  • COMMODORE CAPITAL LP
    1.91M2.17%
  • TCG Crossover Management, LLC
    1.90M2.16%
  • TANG CAPITAL MANAGEMENT LLC
    1.89M2.15%
  • Adage Capital Partners Gp LLC
    1.72M1.95%
  • Geode Capital Management, LLC
    1.72M1.95%

Top Fund Holders

  • Fidelity Growth Company Fund
    2.67M3.02%
  • American Funds SMALLCAP World A
    2.56M2.91%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.49M2.82%
  • iShares Russell 2000 ETF
    1.90M2.15%

Stock Splits

  • Sep 8, 20231:25